J-Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024
Selling, General & Admin	695.14	378.66	606.46
Research & Development	3,015	1,217	1,116
Operating Expenses	3,710	1,596	1,723
Operating Income	-3,710	-1,596	-1,723
Interest & Investment Income	26.77	0	0
Currency Exchange Gain (Loss)	63.24	-6.18	-0.95
Other Non Operating Income (Expenses)	1,004	74.75	88.22
EBT Excluding Unusual Items	-2,616	-1,527	-1,635
Gain (Loss) on Sale of Assets	-6.01	-	-
Asset Writedown	-7.73	-	-11.1
Other Unusual Items	164.35	29.07	-4.8
Pretax Income	-2,465	-1,498	-1,651
Income Tax Expense	1.12	0.99	0.99
Net Income	-2,466	-1,499	-1,652
Net Income to Common	-2,466	-1,499	-1,652
Shares Outstanding (Basic)	13	8	6
Shares Outstanding (Diluted)	13	8	6
Shares Change (YoY)	55.23%	29.92%	-
EPS (Basic)	-195.08	-184.04	-263.57
EPS (Diluted)	-195.08	-184.04	-263.57
Free Cash Flow	-2,253	-1,695	-1,414
Free Cash Flow Per Share	-178.18	-208.12	-225.48
EBITDA	-3,709	-1,595	-1,720
D&A For EBITDA	1.22	0.19	2.26
EBIT	-3,710	-1,596	-1,723